Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines.

Autor:	Mirali S; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Women's College Research Institute, Toronto, Ontario, Canada.; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada., Tang E; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Women's College Research Institute, Toronto, Ontario, Canada.; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada., Drucker AM; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Women's College Research Institute, Toronto, Ontario, Canada.; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Turchin I; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Brunswick Dermatology Center, Fredericton, New Brunswick, Canada.; Probity Medical Research, Waterloo, Ontario, Canada., Gooderham M; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Probity Medical Research, Waterloo, Ontario, Canada.; SKiN Centre for Dermatology, Peterborough, Ontario, Canada.; Department of Medicine, Queens University, Kingston, Ontario, Canada., Levell N; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Norwich Medical School, University of East Anglia, Norwich, United Kingdom.; Department of Dermatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom., Beecker J; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Division of Dermatology, The Ottawa Hospital, Ottawa, Ontario, Canada., Bissonnette R; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Innovaderm Research, Montreal, Quebec, Canada., Catherall H; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada., Lapointe McKenzie JA; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Save Your Skin Foundation, Penticton, British Columbia, Canada., Hawkins N; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Peak Medical Specialty Clinic, Okotoks, Alberta, Canada.; Division of Dermatology, University of Calgary, Calgary, Alberta, Canada., Hong CH; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Probity Medical Research, Waterloo, Ontario, Canada.; Department of Dermatology and Skin Science, University of British Columbia, Surrey, British Columbia, Canada., Kalia S; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada., Papp K; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Probity Medical Research, Waterloo, Ontario, Canada.; K Papp Clinical Research, Waterloo, Ontario, Canada., Chan AW; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Women's College Research Institute, Toronto, Ontario, Canada.; Skin Investigation Network of Canada (SkIN Canada), Toronto, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	JAMA dermatology [JAMA Dermatol] 2023 Jan 01; Vol. 159 (1), pp. 87-94.
DOI:	10.1001/jamadermatol.2022.4590
Abstrakt:	Importance: Patients treated for cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), collectively called keratinocyte carcinoma (KC), are at risk for recurrence, metastasis, and additional primary cutaneous malignant neoplasms. It is unclear how often patients should be seen for follow-up skin examination after initial treatment of KC. Objective: To summarize the recommendations and evaluate the methodological quality of clinical practice guidelines for dermatologic follow-up of patients with BCC and invasive SCC. Evidence Review: PubMed, MEDLINE, and Embase were searched for relevant articles published from January 2010 to March 2022. Search terms included guideline, squamous cell carcinoma, and basal cell carcinoma. National or international guidelines containing recommendations for follow-up frequency after a diagnosis of localized cutaneous KC were included. Quality was assessed using the 6 domains of the Appraisal of Guidelines Research and Evaluation II (AGREE II) tool: (1) scope and purpose; (2) stakeholder development; (3) rigor of development; (4) clarity of presentation; (5) applicability; and (6) editorial independence. The Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) was used to guide study reporting. Findings: Among the 14 guidelines meeting eligibility criteria, there was little consensus on the appropriate follow-up frequency after initial KC treatment. Overall duration of follow-up ranged from a single posttreatment visit to lifelong surveillance. Most guidelines stratified their recommendations by recurrence risk. For low-risk BCC and guidelines that did not stratify by risk, follow-up recommendations ranged from every 6 to 12 months. For high-risk BCC, 1 guideline suggested follow-up every 3 months, while 4 recommended every 6 months. For low-risk SCC, 5 guidelines recommended annual follow-up; 3 guidelines, every 6 months; and 1 guideline, every 3 months. For high-risk SCC, recommendations included a range of follow-up frequencies, spanning every 3 months (n = 5 guidelines), 4 months (n = 1), 6 months (n = 6), or annually (n = 4). One guideline did not use risk stratification and recommended annual screening. The highest scoring AGREE II domain was "scope and purpose," which assessed the guideline's overall objectives, and the lowest scoring was "applicability," which assessed barriers and facilitators to implementation. Conclusions and Relevance: The findings of this systemic review highlight variations in follow-up recommendations for patients after initial treatment for KC. Randomized clinical trials are needed to define an optimal follow-up regimen.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu